Inhibition of Murine AIDS by Combination of AZT and DDCTP-Loaded Erythrocytes

  • A. Fraternale
  • A. Casabianca
  • L. Rossi
  • L. Chiarantini
  • G. Brandi
  • G. Aluigi
  • G. F. Schiavano
  • M. Magnani

Abstract

The human acquired immunodeficiency syndrome (AIDS) is a complex disease induced by the human immunodeficiency virus (1, 2). The development of effective therapies for AIDS has been limited by the lack of animal models that exactly mimic events in human disease. Murine AIDS (MAIDS) is a disease that shares many similarities with human AIDS such as splenomegaly, hypergammaglobulinemia, lymphoadenopathy, T- and B-lymphocyte dysfunctions and profound immunodeficiency (3–5). Since many features of this syndrome are common to those defined in human AIDS, MAIDS serve as a useful experimental model for understanding the pathogenesis of AIDS as well as searching for anti-HIV drugs. In our laboratory this animal model has been used to evaluate the efficacy and toxicity of drugs belonging to the nucleoside analogue family (6, 7), known to be potent in vitro and in vivo inhibitors of HIV-1 replication. Unfortunately, the efficacy of drugs so far used in monotherapy is of limited duration while a number of preliminary studies have already shown that combination therapy is more effective than monotherapy (8, 9). Combination therapy may provide additive or synergistic effect of combined drugs, decreased toxicity and delay of viral resistance. Furthermore, treatment can include drugs acting at different levels of HIV replication or protecting different cell types (i.e. lymphocytes and macrophages). Monocyte/macrophages are important target cells for the human immunodeficiency virus type 1 (HIV-1) (10, 11). They may be chronic recervoirs of HIV-1 and probably play an important role in the pathogenesis of AIDS-related complications such as dementia.

Keywords

Human Immunodeficiency Virus Nucleoside Analogue Acquire Immunodeficiency Syndrome G6PD Gene Symptomatic Human Immunodeficiency Virus 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Barrè-Sinoussi, F., J.C. Chermann, F. Rey, M.T. Nugeyre, S. Chamaret, J. Gruest, C. Dauget, C. Axler-Blin, F. Vezinet, C. Ronzioux, W. Rozembaum and L. Montagnier (1983). Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immunodeficiency syndrome (AIDS). Science, 220, 868–871.PubMedCrossRefGoogle Scholar
  2. 2.
    Popovic, M., M.G. Sarngadharan, E. Read and R.C. Gallo (1984). Detection, isolation, and continuous production of cytopathic retrovirus (HTLV-III) from patients with AIDS and pre-AIDS. Science, 224, 497–501.PubMedCrossRefGoogle Scholar
  3. 3.
    Mosier, D.E., R.A. Yetter and H.C. III Morse (1985). Retrovirus induction of acute lymphoproliferative disease and profound immunosuppression in adult C57BL/6 mice. J. Exp. Med. 61, 767–772.Google Scholar
  4. 4.
    Morse, H.C. III, S.K. Chattopadhyay, N. Makino, T.N. Fredrickson, A.W. Hugin and J.W. Hartley (1992). Retrovirus-induced immunodeficiency in the mouse: MAIDS as a model for AIDS. AIDS 6, 607–621.PubMedCrossRefGoogle Scholar
  5. 5.
    Jolicoeur, P. (1991). Murine acquired immunodeficiency syndrome (MAIDS): an animal model to study the AIDS pathogenesis. Faseb J. 5, 2398–2405.PubMedGoogle Scholar
  6. 6.
    Brandi, G., A. Casablanca, G.F. Schiavano, L. Rossi, A. Fraternale, A. Albano and M. Magnani (1995). Efficacy and toxicity of long-term administration of 2′,3′-dideoxycytidine in the LP-BM5 murine-induced immunodeficiency model. Antiv. Chem. & Chemother. 6(3), 153–161.Google Scholar
  7. 7.
    Rossi, L., G. Brandi, A. Fraternale, G.F. Schiavano, L. Chiarantini and M. Magnani (1993). Inhibition of murine retrovirus induced immunodeficiency disease by dideoxycytidine and dideoxycytidine 5′-triphosphate. J. of AIDS 6, 1179–1186.Google Scholar
  8. 8.
    Yarchoan, R.K.M., J.A. Lietzau, B.-Y. Nygen, O.W. Brawley, J.M. Pluda, K.M. Wyvill, S.M. Steinberg, R. Agbaria, H. Mitsuya and S. Broder (1994). A randomized pilot study of alternating and simultaneous regimens of zidovudine (AZT) and didanosine (ddI) in patients with symptomatic human immunodeficiency virus (HIV) infection. J. Infect. Dis. 169, 9–17.PubMedCrossRefGoogle Scholar
  9. 9.
    Johnson, V.A., P. Merrill, T.C. Chou and M.S. Hirsch (1992). Human immunodeficiency virus type 1 (HIV-1) inhibitory interactions between protease inhibitor R. 31-8959 and zidovudine, 2′,3′-dideoxycytidine, or recombinant interferon alfa against zidovudine-sensitive or resistant HIV-1 in vitro. J. Infect. Dis. 166, 1143–1146.PubMedCrossRefGoogle Scholar
  10. 10.
    Gartner, S., P. Markovits, D.M. Markovits, M.H. Kaplan, R.C. Gallo and M. Popovic (1986). The role of mononuclear phagocytes in HTLV-IH LAV infection. Science, 233, 215–219.PubMedCrossRefGoogle Scholar
  11. 11.
    Ho, D.D., T.R. Rota and M.S. Hirsch (1986). Infection of monocyte/macrophages by human T/lymphotropic virus type III. J. Clin. Invest., 77, 12–15.CrossRefGoogle Scholar
  12. 12.
    Magnani, M., A. Casabianca, L. Rossi, A. Fraternale, G. Brandi, L. Silvotti and G. Piedimonte (1995). Inhibition of HIV-1 and LP-BM5 replication in macrophages by dideoxycytidine and dideoxycytidine 5′-triphosphate. Antiv. Chem. & Chemother., 6(5), 312–319.Google Scholar
  13. 13.
    Magnani, M., L. Rossi, G. Brandi, G.F. Schiavano, M. Montroni and G. Piedimonte (1992). Targeting antiretroviral nucleoside analogues in phosphorylated form to macrophages: In vitro and in vivo studies. Proc. Natl. Acad. Sci., 89, 6477–6481.PubMedCrossRefGoogle Scholar
  14. 14.
    Ohnota, H., Y Okada, H. Ushijima, T. Kitamura, K. Komuro and T. Mizuochi (1990). 3′-azido-3′-deoxythymidine prevents induction of murine acquired immunodeficiency syndrome in C57BL/10 mice infected with LP-BM5 murine leukemia viruses, a possible animal model for antiretroviral drug screening. Antimicr. Agents and Chemother., 34(4), 605–609.CrossRefGoogle Scholar
  15. 15.
    Basham, T, CD. Rios, T. Holdener and T.C. Merigan (1990). Zidovudine (AZT) reduces virus titer, retards immune dysfunction, and prolongs survival in the LP-BM5 murine induced immunodeficiency model. J. Infect. Dis. 161, 1006–1009.PubMedCrossRefGoogle Scholar
  16. 16.
    Mosier, D.E., R.A. Yetter and H.C. III Morse (1987). Functional T lymphocytes are required for a murine retrovirus induced immunodeficiency disease (MAIDS). J. Exp. Med., 165, 1737–1742.PubMedCrossRefGoogle Scholar
  17. 17.
    Aziz, D.C., Z. Hanna and P. Jolicoeur (1989). Severe immunodeficiency disease induced by a defective murine leukemia virus. Nature 338, 505–508.PubMedCrossRefGoogle Scholar
  18. 18.
    Kurdi-Haidar, B., P.J. Mason, A. Berrebi, G. Ankra-Badu, A. Al-Ali, A. Oppenheim and L. Luzzatto. (1990). Origin and spread of the glucose-6-phosphate dehydrogenase variant (G6PD-Mediterranean) in the Middle east. Am. J. Hum. Genet. 47, 1013–1019.PubMedGoogle Scholar
  19. 19.
    Chattopadhyay, S.K., D.N. Sengupta, T.N. Fredrickson, H.C. III Morse and J.W. Hartley (1991). Characteristics and contributions of defective, ecotropic and mink cell focus-inducing viruses in a retrovirus induced immunodeficiency syndrome of mice. J. Virol., 65, 4232–4241.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1997

Authors and Affiliations

  • A. Fraternale
    • 1
  • A. Casabianca
    • 1
  • L. Rossi
    • 1
  • L. Chiarantini
    • 1
  • G. Brandi
    • 2
  • G. Aluigi
    • 1
  • G. F. Schiavano
    • 2
  • M. Magnani
    • 1
  1. 1.Institute of Biological Chemistry “Giorgio Fornaini”University of UrbinoItaly
  2. 2.Institute of HygieneUniversity of UrbinoItaly

Personalised recommendations